Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 17.9 -2.45% -0.45
VNDA closed down 2.45 percent on Wednesday, March 20, 2019, on 41 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical VNDA trend table...

Date Alert Name Type % Chg
Mar 20 Oversold Stochastic Weakness 0.00%
Mar 19 Narrow Range Bar Range Contraction -2.45%
Mar 19 NR7 Range Contraction -2.45%
Mar 19 Inside Day Range Contraction -2.45%
Mar 19 Oversold Stochastic Weakness -2.45%
Mar 18 Down 3 Days in a Row Weakness -1.76%
Mar 18 Oversold Stochastic Weakness -1.76%
Mar 15 Volume Surge Other -2.13%
Mar 15 Stochastic Reached Oversold Weakness -2.13%
Mar 15 BB Squeeze Ended Range Expansion -2.13%

Older signals for VNDA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.
Biopharmaceutical Chemical Compounds Organic Compounds Oncology Chemotherapy Schizophrenia Central Nervous System Disorders Depression Major Depressive Disorder Nausea Pyridines Vomiting Pruritus Treatment Of Central Nervous System Disorders Treatment Of Major Depressive Disorder Insomnia Sedatives Chemotherapy Induced Nausea Chemotherapy Induced Nausea And Vomiting Fanapt Iloperidone
Is VNDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 33.44
52 Week Low 13.88
Average Volume 1,002,598
200-Day Moving Average 22.0059
50-Day Moving Average 23.06
20-Day Moving Average 19.3545
10-Day Moving Average 18.564
Average True Range 0.8283
ADX 36.01
+DI 12.3498
-DI 33.6867
Chandelier Exit (Long, 3 ATRs ) 18.9251
Chandelier Exit (Short, 3 ATRs ) 20.1449
Upper Bollinger Band 21.1376
Lower Bollinger Band 17.5714
Percent B (%b) 0.09
BandWidth 18.425689
MACD Line -1.1579
MACD Signal Line -1.2512
MACD Histogram 0.0933
Fundamentals Value
Market Cap 802.95 Million
Num Shares 44.9 Million
EPS -0.23
Price-to-Earnings (P/E) Ratio -77.83
Price-to-Sales 4.05
Price-to-Book 4.81
PEG Ratio -2.09
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.12
Resistance 3 (R3) 19.17 18.82 18.91
Resistance 2 (R2) 18.82 18.51 18.79 18.84
Resistance 1 (R1) 18.36 18.32 18.19 18.31 18.78
Pivot Point 18.01 18.01 17.92 17.98 18.01
Support 1 (S1) 17.55 17.70 17.38 17.50 17.02
Support 2 (S2) 17.20 17.51 17.17 16.96
Support 3 (S3) 16.74 17.20 16.89
Support 4 (S4) 16.69